WallStreetZenWallStreetZen

NASDAQ: ARCT
Arcturus Therapeutics Holdings Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Arcturus Therapeutics Holdings revenue was $122.12M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 30, 2025 was $28.3M, down 3.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ARCT annual revenue was $152.3M, with -8.7% growth year-over-year.

ARCT past revenue growth

How has ARCT's revenue growth performed historically?

Company
-25.47%
Industry
150.55%
Market
20.46%
ARCT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ARCT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ARCT's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ARCT revenue history

Current Revenue
$122.1M
Current Earnings
-$60.2M
Current Profit Margin
-49.3%

Be the first to know when ARCT announces revenue.

ARCT Revenue History By Year

ARCT Yearly RevenueARCT RevenueARCT ChangeARCT Revenue Growth
2024-12-31$152.31M-$14.49M-8.69%
2023-12-31$166.80M-$39.20M-19.03%
2022-12-31$206.00M$193.64M+1,566.79%
2021-12-31$12.36M$2.82M+29.56%
2020-12-31$9.54M-$11.25M-54.12%
2019-12-31$20.79M$5.04M+31.97%
2018-12-31$15.75M$2.76M+21.20%
2017-12-31$13.00M-$7.38M-36.23%
2016-12-31$20.38M$14.24M+232.06%
2015-12-31$6.14MN/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A
2011-12-31$0.00N/AN/A

1 of 1

Arcturus Therapeutics Holdings Revenue FAQ

What was ARCT's revenue last quarter?

On Invalid Date, Arcturus Therapeutics Holdings (NASDAQ: ARCT) reported Q2 2025 revenue of $28.30 million up 43.24% year over year. In the same quarter last year, Arcturus Therapeutics Holdings's revenue was $49.86 million.

What was Arcturus Therapeutics Holdings's revenue in 2024?

Arcturus Therapeutics Holdings's annual revenue for the twelve months ending Dec 31, 2024 was $152.31 million, a 8.69% decrease year over year.

How much does Arcturus Therapeutics Holdings make in a day?

Based on Arcturus Therapeutics Holdings annual revenue for the past five years, ARCT makes an average of $299,729.32 per day.

What was Arcturus Therapeutics Holdings's annual revenue growth in the past year?

As of Q4 2025, Arcturus Therapeutics Holdings's revenue has grown -25.47% year over year. This is 176.02 percentage points lower than the US Biotechnology industry revenue growth rate of 150.55%. Arcturus Therapeutics Holdings's revenue in the past year totaled $122.12 million.

How much does Arcturus Therapeutics Holdings make in a year?

Arcturus Therapeutics Holdings's revenue by year for the past five years is:
  • Arcturus Therapeutics Holdings's revenue for the twelve months ending Dec 31, 2024 was $152.31 million, a 8.69% decrease year over year.
  • Arcturus Therapeutics Holdings's annual revenue for Dec 31, 2023 was $166.80 million, a 19.03% decrease from 2022.
  • Arcturus Therapeutics Holdings's annual revenue for 2022 was $206.00 million, a 1,566.79% increase from 2021.
  • Arcturus Therapeutics Holdings's annual revenue for 2021 was $12.36 million, a 29.56% increase from 2020.
  • Arcturus Therapeutics Holdings's annual revenue for 2020 was $9.54 million, a 54.12% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.